Health & Fitness
Health and Fitness
Health and Fitness
Thu, December 8, 2011
Wed, December 7, 2011
Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December... -- BOONTON, N.J., Dec. 7, 2011 /PRNewswire/ --
Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
BOONTON, N.J., Dec. 7, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE),a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will be presenting a corporate overview at the 22nd Annual Oppenheimer Healthcare Conference being held in New York City. Mr. Palmer's live presentation is scheduled to begin at 4:10 p.m. ET on Tuesday, December 13, 2011.
A live webcast of the presentation will be available by logging on to the Investors and Media section under the Events tab of the Unigene web site, [ http://www.unigene.com ]. Participants should allow approximately five to 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.
About Unigene Laboratories, Inc.:
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
[ jthomas@unigene.com ]
Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
[ jrando@tiberend.com ] / [ amielach@tiberend.com ]
SOURCE Unigene Laboratories, Inc.
[ Back to top ] RELATED LINKS
[ http://www.unigene.com ]
